Exagen Inc. XGN Warrants and Rights Outstanding
Warrants and Rights Outstanding at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightOutstanding.
The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s warrants and rights outstanding.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s warrants and rights outstanding?
- Exagen Inc. (XGN) reported warrants and rights outstanding of 131 in Q1 2026.
- How has Exagen Inc.'s warrants and rights outstanding changed year-over-year?
- Exagen Inc.'s warrants and rights outstanding decreased by 100.0% year-over-year, from 1.1M to 131.
- What is the long-term trend for Exagen Inc.'s warrants and rights outstanding?
- Over 5 years (2020 to 2025), Exagen Inc.'s warrants and rights outstanding has grown at a 13.9% compound annual growth rate (CAGR), from 426.8K to 819.4K.
- What does warrants and rights outstanding mean?
- The total number of warrants and rights currently held by third parties that are convertible into common equity. This figure is critical for calculating fully diluted share counts and understanding potential future equity dilution. It serves as a measure of the company's historical capital-raising activities involving equity-linked instruments.